Lebwohl, M. G., J. L. Sugarman, L. S. Gold, T. Lin, and G. Martin. “Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S29, doi:10.25251/skin.3.supp.29.